pembrolizumab
merck
['keynote-189']
 presenting 5-yr data for keynote-189 trial at #esmo22. as expected, higher the pd-l1, better are the objective responses. 5 yr os almost double that of placebo. 
Thoracic Medical Oncologist/Pulmonologist; Professor #PGIMER; #LCSM #lungcancer; Close a/w @ASCO @IASLC @myESMO; Tweets Personal (not official/medical opinions)